CSI Market
Sign In | Register

Horizon Therapeutics Public Limited (HZNP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access HZNP Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Horizon Therapeutics Public Limited manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2023)
6 Months 		(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Operating Activities
Income181.76
Depreciation & amortization191.15
Amortization of Other Assets2.78
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.77
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total-2.00
Share-based Compensation118.39
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain On Purchase Of Business-
Trading Securities Unrealized Holding Gain-
Commitment Fee Paid On Notes Payable-
Gains Losses On Induced Conversion And Extinguishment Of Debt-
Increase Decrease In Accounts Trade Discounts And Rebates-
Derivative Loss On Derivative-
Gain Loss On Cash Payments Associated With Inducements Conversion And Debt Extinguishment-
Payments Related To Term Loan Refinancing-
Gain Loss On Disposition Of Assets Excluding Unpaid Transaction Costs And Indemnification Asset-
Foreign Exchange Gain Loss And Other Adjustments-6.14
Increase Decrease In Accrued Trade Discounts And Rebates-0.55
Income taxes0.00
Gain (Loss) on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-41.14
Increase (Decrease) in Accounts Payable-70.23
Increase (Decrease) in Accrued Liabilities63.39
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-200.77
Other Working Capital11.93
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities247.79
Investing Activities
Capital Expenditures-42.59
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment Related To License Agreement-
Change In Escrow Deposit For Property Purchase-
Payments To Escrow Deposit For Property Purchase-
Payment Related To License And Collaboration Agreements-
Payments Related To License And Collaboration Agreements-15.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments-4.18
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-61.78
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-8.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.96
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-92.06
Proceeds From Issuance Of Convertible Debt-
Purchase Of Call Options-
Proceeds From At Market Issuance Of Common Stock Net Of Issuance Costs-
Debt Conversion Original Debt Amount-
Noncash Or Part Noncash Acquisition Other Liabilities Assumed-
Noncash Or Part Noncash Acquisition Intangible Assets Acquired-
Payment Of Original Issue Discount Upon Repayment Of Debt-
Proceeds From Repayments Of Related To Employee Stock Purchase Plan-
Contingent Consideration Proceeds From Divestitures-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-79.09
Effect of exchange rate on cash flow4.91
Discontinued operations0.00
Free Cash Flow205.20
Total Cash Flow111.83
4 historic quarters locked

Sign in to unlock the full Horizon Therapeutics Public Limited cash flow history.

Sign In Create Free Account

About Horizon Therapeutics Public Ltd Co Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-039388

Figures are derived from filed reports and may be restated. Historical data is subject to revision.